MediPal Lifts Profit Forecasts for Fiscal Year Ending March 2027
MediPal (TYO:7459) raised its attributable profit forecast for the fiscal year ending March 31, 2027, to 43 billion yen from 39 billion yen following the completion of the tender offer for Paltac's (TYO:8283) shares. The pharmaceutical wholesaler lifted its earnings per share estimate to 210.06 yen from 190.52 yen, while net sales remain unchanged at 3.944 trillion yen. The revision follows the completion of Medipal's tender offer for Paltac on July 7, with squeeze-out procedures expected around August to make Paltac a wholly owned subsidiary. As a result, profits previously attributed to non-controlling interests will now accrue entirely to Medipal.
MediPal (TYO:7459) raised its attributable profit forecast for the fiscal year ending March 31, 2027, to 43 billion yen from 39 billion yen following the completion of the tender offer for Paltac's (TYO:8283) shares.
The pharmaceutical wholesaler lifted its earnings per share estimate to 210.06 yen from 190.52 yen, while net sales remain unchanged at 3.944 trillion yen.
The revision follows the completion of Medipal's tender offer for Paltac on July 7, with squeeze-out procedures expected around August to make Paltac a wholly owned subsidiary.
As a result, profits previously attributed to non-controlling interests will now accrue entirely to Medipal.